Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-06-15 4:30 pm Purchase | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,537,771 6.1% | 671,432 (+35.98%) | View |
| 2023-06-09 4:15 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | ExodusPoint Capital Management LP | 1,414,824 5.8% | 1,414,824 (New Position) | View |
| 2023-06-08 4:30 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | INTEGRATED CORE STRATEGIES (US) LLC | 1,397,382 5.7% | 1,397,382 (New Position) | View |
| 2023-05-24 5:15 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Point72 Asset Management L.P. | 2,121,170 8.7% | 2,121,170 (New Position) | View |
| 2023-02-24 4:00 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | TANG CAPITAL PARTNERS LP | 1,355,826 5.8% | 1,355,826 (New Position) | View |
| 2023-02-14 3:15 pm Sale | 13G | Elevation Oncology, Inc. ELEV | Cormorant Asset Management LP | 1,952,032 8.38% | -31,136 (-1.57%) | View |
| 2023-02-13 6:05 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 2,312,200 9.9% | 700,502 (+43.46%) | View |
| 2023-02-08 5:00 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,876,561 12.34% | 10,413 (+0.36%) | View |
| 2022-09-30 5:24 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | K2 HealthVentures Equity Trust LLC | 1,566,464 6.3% | 1,566,464 (New Position) | View |
| 2022-09-26 4:21 pm Unchanged | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 1,866,339 8% | 0 (Unchanged) | View |
| 2022-07-11 10:28 am Sale | 13G | Elevation Oncology, Inc. ELEV | Driehaus Capital Management LLC | 1,044,244 4.49% | -458,524 (-30.51%) | View |
| 2022-06-10 09:02 am Sale | 13G | Elevation Oncology, Inc. ELEV | Driehaus Capital Management LLC | 1,502,768 6.46% | -479,695 (-24.20%) | View |
| 2022-05-27 5:26 pm Sale | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 1,866,339 8.03% | -741,828 (-28.44%) | View |
| 2022-02-14 4:21 pm Sale | 13G | Elevation Oncology, Inc. ELEV | Boxer Capital LLC | 872,780 3.8% | -468,750 (-34.94%) | View |
| 2022-02-14 1:46 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 1,611,698 6.9% | 1,611,698 (New Position) | View |
| 2022-02-14 12:16 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,866,148 12.33% | 2,866,148 (New Position) | View |
| 2022-02-14 09:19 am Purchase | 13G | Elevation Oncology, Inc. ELEV | Driehaus Capital Management LLC | 1,982,463 8.54% | 1,982,463 (New Position) | View |
| 2022-02-08 4:15 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Qiming U.S. Healthcare GP II LLC | 2,370,142 10.2% | 2,370,142 (New Position) | View |
| 2022-01-18 4:00 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Vertex Global HC Fund II Pte. Ltd. | 2,307,642 9.94% | 2,307,642 (New Position) | View |
| 2021-07-09 4:31 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Boxer Capital LLC | 1,341,530 5.9% | 1,341,530 (New Position) | View |